Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin
Open Access
- 1 September 2000
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 165 (5) , 2491-2499
Abstract
We have previously identified a 13-residue cyclic peptide, Compstatin, that binds to complement component C3 and inhibits complement activation. Herein, we describe the binding kinetics, structure-activity relationship, and biotransformation of Compstatin. Biomolecular interaction analysis using surface-plasmon resonance showed that Compstatin bound to native C3 and its fragments C3b and C3c, but not C3d. While binding of Compstatin to native C3 was biphasic, binding to C3b and C3c followed the 1:1 Langmuir binding model; the affinities of Compstatin for C3b and C3c were 22- and 74-fold lower, respectively, than that of native C3. Analysis of Compstatin analogs synthesized for structure-function studies indicated that 1) the 11-membered ring between disulfide-linked Cys2-Cys12 constitutes a minimal structure required for optimal activity; 2) retro-inverso isomerization results in loss of inhibitory activity; and 3) some residues of the type I β-turn segment also interact with C3. In vitro studies of Compstatin in human blood indicated that a major pathway of biotransformation was the removal of Ile1, which could be blocked by N-acetylation of the peptide. These findings indicate that acetylated Compstatin is stable against enzymatic degradation and that the type I β-turn segment is not only critical for preservation of the conformational stability, but also involved in intermolecular recognition.Keywords
This publication has 40 references indexed in Scilit:
- Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of ApoptosisScience, 1997
- CorrespondenceCardiovascular Research, 1997
- Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement.Journal of Experimental Medicine, 1996
- A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitroEuropean Journal of Immunology, 1996
- Recent developments in retro peptides and proteins — an ongoing topochemical explorationTrends in Biotechnology, 1995
- The Retro-inverso Form of a Homeobox-Derived Short Peptide Is Rapidly Internalized by Cultured Neurons: A New Basis for an Efficient Intracellular Delivery SystemBiochemical and Biophysical Research Communications, 1995
- Therapeutic uses of recombinant complement protein inhibitorsSpringer Seminars in Immunopathology, 1994
- Interaction of cyclosporin A with an Fab fragment or cyclophilin Affinity measurements and time‐dependent changes in bindingFEBS Letters, 1993
- Synthetic peptide inhibitors of complement serine proteases—II. Effects on hemolytic activity and production of C3a and C4aMolecular Immunology, 1988
- Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.Journal of Experimental Medicine, 1981